| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10219930 | European Urology | 2018 | 8 Pages |
Abstract
In this multicentre study of 625 patients undergoing focal therapy using high-intensity focused ultrasound (HIFU), failure-free survival, metastasis-free survival, cancer-specific survival, and overall survival were 88%, 98%, 100%, and 99%, respectively. Urinary incontinence (any pad use) was 2%. Focal HIFU therapy for patients with clinically significant prostate cancer that has not spread has a low probability of side effects and is effective at 5 yr.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Stephanie Guillaumier, Max Peters, Manit Arya, Naveed Afzal, Susan Charman, Tim Dudderidge, Feargus Hosking-Jervis, Richard G. Hindley, Henry Lewi, Neil McCartan, Caroline M. Moore, Raj Nigam, Chris Ogden, Raj Persad, Karishma Shah, Jan van der Meulen,